COMMUNIQUÉS West-GlobeNewswire

Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments
28/07/2026
Positive proof-of-concept clinical data show substantial improvements in visual acuity in limbal stem cell deficiency ( LSCD) patients treated with CSB-001 Pivotal studies for CSB-001 in LSCD planned for 1H 2027 Series [...]
HealthBegins Launches Online Learning Platform to Scale ‘Upstreamist’ Movement with Expert-Led Instruction and Resources
28/07/2026
HealthBegins Academy combines expert instruction, applied frameworks and flexible learning formats to turn health equity strategies into sustainable, scalable practices PASADENA, Calif., July 28, 2026 (GLOBE NEWSWIRE [...]
BiomX And Water.IO Agree To Updated Zorronet Acquisition Terms
28/07/2026
Revised agreement provides BiomX with additional flexibility to support Zorronet while further aligning BiomX and Water IO around Zorronet's long-term success NETANYA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- BiomX Inc [...]
Codexis to Report Second Quarter 2026 Financial Results on August 11
28/07/2026
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it [...]
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
28/07/2026
Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- [...]
Oak Hill Bio Announces Dosing of First Participant in BEACON Phase 3 Clinical Trial of Rugonersen in Angelman Syndrome
28/07/2026
Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy in development for Angelman syndrome, advanced into the pivotal Phase 3 BEACON clinical trial Angelman syndrome affects approximately 30, [...]
Slate Medicines Establishes Clinical and Scientific Advisory Boards to Advance Next-Generation Migraine Prevention Therapeutics
28/07/2026
Leading neurologists and researchers to provide strategic and clinical guidance as Slate Medicines progresses SLTE-1009 and a broader pipeline of migraine therapeutics. RALEIGH, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- [...]
Cato Healthcare Supply Strengthens Executive Leadership Team
28/07/2026
DALLAS, July 28, 2026 (GLOBE NEWSWIRE) -- Cato Healthcare Supply, the healthcare industry's leading revenue preservation and off-contract procurement platform, today announced the promotion and appointment of four [...]
Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
28/07/2026
MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook [...]
Exagen Inc. to Participate in Upcoming Investor Conference
28/07/2026
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord [...]
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
28/07/2026
Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients eligible annually [...]
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
28/07/2026
– ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data [...]
Starget Pharma Expands Scientific Advisory Board with Appointment of Two Global Leaders in Radiopharmaceutical Therapy
28/07/2026
Dr. Oliver Sartor brings more than 35 years advancing the clinical development and commercialization of oncology and radiopharmaceuticals Professor Michael Hofman brings more than 20 years pioneering molecular imaging [...]
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
28/07/2026
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
28/07/2026
Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (“FBS”) and Scripps Research demonstrates C1's potential to accelerate vaccine and monoclonal antibody development, expand platform adoption [...]
Grief goes global on screen as first-of-its-kind festival receives over 500 films from six continents
28/07/2026
Filmmakers across more than 50 countries submitted work on loss and healing, signaling cinema's growing power as a shared language for grief. New York, NY, July 28, 2026 (GLOBE NEWSWIRE) -- Grief Fest™ , the first [...]
Applied Biologics Expands National Commercial Payer Engagement Strategy for XWRAP®
28/07/2026
SCOTTSDALE, Ariz., July 28, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
28/07/2026
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré’s strategy to build a trusted women’s health ecosystem spanning products, education and access to care [...]
New Pharmacoeconomic Analysis Finds KYZATREX® Could Cut the VA’s Total Cost of Testosterone Care by Nearly Half for America’s Veterans
28/07/2026
Model projects up to $16.2 million in potential annual savings for every 50,000 veterans transitioned from office-administered injectable therapy — while expanding treatment choice RALEIGH, N.C., July 28, 2026 (GLOBE [...]

Pages